PATENTS

Medlab owns and runs an Office of the Gene Technology Regulator (OGTR) approved PC2 Biologic facility in NSW, Australia.


This is the primary site for research projects.


Presently we are involved in early phase drug discovery in 5 key areas:

  1. Obesity
  2. Chronic Kidney Disease
  3. Depression
  4. Musculoskeletal muscle loss associated with ageing
  5. Non-opioid pain management

 

Medlab has multiple patents pending on our products:

 

Patent Portfolio as at 13/08/2018

Product

Jurisdiction

Description

Application Number

Filling Date

Status

T2Biotic

Australia

Probiotic composition and uses thereof for obesity-related disorders

2015258769

11/5/15

Filed

T2Biotic

Australia (innovation)

Probiotic composition and uses thereof for obesity-related disorders

2-17101478

30/10/17

Granted

NRGBiotic

Australia

Probiotic combinations and uses thereof

2015202755

21/5/15

Granted

NRGBiotic

Australia (innovation)

Probiotic combinations and uses thereof 

2015100928

6/8/15

Granted

EnBiotic

Australia (Innovation)

Probiotic and enzyme containing compositions and uses thereof

2015100952

17/7/15

Granted

CKD

Australia

Probiotic compositions and uses thereof (i)

2018903306

4/9/17

Provisional application filed

Complete application due 5 Sep 2019

Cannabinoids

Australia

Probiotic compositions and uses thereof (ii)

2018903305

4/9/17

Provisional application filed

Complete application due 5 Sep 2019

Orotate

Australia

Treatment for depression and depressive disorders

2015337800

28/10/15

Filed

Orotate

Canada

Treatment for depression and depressive disorders

2964971

28/10/15

Filed

Orotate

Europe

Treatment for depression and depressive disorders

15854029.4

28/10/15

Filed

Orotate

New Zealand

Treatment for depression and depressive disorders

731151

28/10/15

Filed

Orotate

Singapore

Treatment for depression and depressive disorders

11201703193X

28/10/15

Under Examination

Orotate

United States

Treatment for depression and depressive disorders

15/523271

28/10/15

Filed

ORSbiotic

Australia (Innovation)

Probiotic compositions for rehydration

2016100500

2/5/16

Granted

GastroDaily

Australia (Innovation)

Yeast-containing compositions for gastrointestinal health

2016100499

2/5/16

Granted

W8Biotic

Australia (Innovation)

Probiotic composition for weight management

2016100501

2/5/16

Granted

Nanocelle

Australia

Transmucosal and transdermal delivery systems

PCT/US2016/020468

2/3/16

Filed

Nanocelle

Canada

Transmucosal and transdermal delivery systems

2978179

2/3/16

Filed

Nanocelle

Europe

Transmucosal and transdermal delivery systems

16759418.3

2/3/16

Filed

Nanocelle

New Zealand

Transmucosal and transdermal delivery systems

735138

2/3/16

Filed

Nanocelle

Singapore

Transmucosal and transdermal delivery systems

11201707068X

2/3/16

Examination Requested

Nanocelle

United States

Transmucosal and transdermal delivery systems

15/555038

2/3/16

Filed

Nanocelle

Hong Kong

Transmucosal and transdermal delivery systems

18103321.4

8/3/2018

Filed

API Degradation

Australia

Protection of plant extracts and compounds from degradation

PCT/AU2017/050430

11/5/17

Filed

30 month national phase entry deadline 11 Nov 2018

T2Biotic - Intestinal Microbiota

Australia

microbiota in pre-diabetes and type 2 diabetes

2017904443

1/11/17

provisional application fixed 

Complete application due 1 Nov 18

T2Biotic -SCFA

Australia

Modulation of intestinal microbiota in pre-diabetes and type 2 diabetes

2017904444

1/11/17

Provisional application filed. complete application due 1 Nov 2018

Hydrogel Formulation

Australia

NanocCelle Bacteria

In draft

11/5/16

provisional specification proposed